Abstract
Erectile dysfunction (ED) is a common problem, particularly in older men. The production of penile erection involves an interplay between autonomic nerves and locally released vasoactive mediators. Endothelin-1 (ET-1) is a peptide released from endothelium in the corpus cavernosum, which causes smooth muscle contraction. Recent studies have investigated the physiological significance of ET-1 in the control of erectile function and it may play a role in detumescence. There is also much evidence to link ET-1 to risk factors for ED. ET-1 antagonists may prove beneficial in the treatment of ED and also in prevention of long term deterioration of erectile function. These antagonists may also find a role when used in combination with agents, which are established for the treatment of ED.
Keywords: Endothelin Antagonists, Erectile Dysfunction ED, NO Synthase NOS, Vasoactive Mediators, Ischaemic heart disease, Vasoactive intestinal polypeptide
Current Drug Targets
Title: Normal and Pathological Erectile Function The Potential Clinical Role of Endothelin-1 Antagonists
Volume: 1 Issue: 3
Author(s): M. A. Khan, R. C. Calvert, M. E. Sullivan, C. S. Thomson, F. H. Mumtaz, R. J. Morgan and D. P. Mikhailidis
Affiliation:
Keywords: Endothelin Antagonists, Erectile Dysfunction ED, NO Synthase NOS, Vasoactive Mediators, Ischaemic heart disease, Vasoactive intestinal polypeptide
Abstract: Erectile dysfunction (ED) is a common problem, particularly in older men. The production of penile erection involves an interplay between autonomic nerves and locally released vasoactive mediators. Endothelin-1 (ET-1) is a peptide released from endothelium in the corpus cavernosum, which causes smooth muscle contraction. Recent studies have investigated the physiological significance of ET-1 in the control of erectile function and it may play a role in detumescence. There is also much evidence to link ET-1 to risk factors for ED. ET-1 antagonists may prove beneficial in the treatment of ED and also in prevention of long term deterioration of erectile function. These antagonists may also find a role when used in combination with agents, which are established for the treatment of ED.
Export Options
About this article
Cite this article as:
Khan A. M., Calvert C. R., Sullivan E. M., Thomson S. C., Mumtaz H. F., Morgan J. R. and Mikhailidis P. D., Normal and Pathological Erectile Function The Potential Clinical Role of Endothelin-1 Antagonists, Current Drug Targets 2000; 1 (3) . https://dx.doi.org/10.2174/1389450003349164
DOI https://dx.doi.org/10.2174/1389450003349164 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epidemiology of Upper Gastrointestinal Damage Associated with Low-Dose Aspirin
Current Pharmaceutical Design Defensive and Offensive Cross-Reactive Antibodies Elicited by Pathogens: The Good, the Bad and the Ugly
Current Medicinal Chemistry Space Flight Induces Reduction of Paramyosin and Troponin T: Proteomic Analysis of Space-Flown Caenorhabditis elegans
Current Biotechnology <i>Prunella vulgaris</i> L: Critical Pharmacological, Expository Traditional Uses and Extensive Phytochemistry: A Review
Current Drug Discovery Technologies Sleep Duration as a Risk Factor for Cardiovascular Disease- a Review of the Recent Literature
Current Cardiology Reviews Prediction of MicroRNA–disease Associations by Matrix Completion
Current Proteomics Can the Electrophysiological Action of Rosiglitazone Explain its Cardiac Side Effects?
Current Medicinal Chemistry Smoking and Cognition
Current Drug Abuse Reviews The Role of Novel Biomarkers of Cardiovascular Disease in Chronic Kidney Disease: Focus on Adiponectin and Leptin
Current Cardiology Reviews Peroxisome Proliferator-Activated Receptor (PPAR) in Metabolic Syndrome and Type 2 Diabetes Mellitus
Current Diabetes Reviews Nutritional Status and Lipid Profile in HIV-Infected Adults
Endocrine, Metabolic & Immune Disorders - Drug Targets Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders
Current Vascular Pharmacology Phytocannabinoids and Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Cranberry as Promising Natural Source of Potential Anticancer Agents: Current Evidence and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Orthotopic Heart Transplantation in Patients with Univentricular Physiology
Current Cardiology Reviews A Practical Comprehensive Approach to Management of Acute Decompensated Heart Failure
Current Cardiology Reviews Stress Hormone-Mediated DNA Damage Response -- Implications for Cellular Senescence and Tumour Progression
Current Drug Targets Clinical Use of Neurophysiological Biomarkers and Self-Assessment Scales to Predict and Monitor Treatment Response for Psychotic and Affective Disorders
Current Pharmaceutical Design Editorial (Thematic Issue: Induced Pluripotent Stem Cells (iPSCs) in the Gastroenterology and Hepatology: from Basic Research to Clinical Applications)
Current Stem Cell Research & Therapy Crosstalk Signalling Role in Modulation of Drugs Side Effects
Current Molecular Pharmacology